Business
CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors
REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the appointment of Alisa Lask to its Board of Directors. Ms. Lask is based in the United States and has held leadership roles in medical aesthetics at both Galderma and Allergan. She will be the seventh independent member of the CollPlant Board.\n\n \n \n \n \n \n \n\n \n\"Alisa brings a strong background in global strategy and marketing that will be very helpful to maximizing the value of co-developments with industry leaders in medical aesthetics and 3D bioprinting,\" said Yehiel Tal, CEO of CollPlant. \"Alisa is an excellent addition to our Board. She has valuable insights and a diverse skill set that will play an integral role in our mission to help people live longer and better with products developed through our plant-based collagen technology platform.\"\n\"CollPlant has been rapidly expanding its commercial partnerships with global leaders and I am delighted to join the Board of Directors during this exciting time. I look forward to contributing to CollPlant's future growth and success as the company continues to innovate in the field of regenerative medicine, especially relating to aesthetics,\" said Ms. Lask. \n\"CollPlant is committed to adding Board members with a track record of accomplishment and a strong strategic vision,\" commented CollPlant's Chairman, Dr. Roger J. Pomerantz. \"We welcome Alisa Lask at this important stage of the Company's growth to help leverage our strong R&D capabilities and external collaborations to develop innovative regenerative medicine products.\"\nMs. Lask is the former Vice President and General Manager of US Aesthetics at Galderma. Previously, she was a Senior Director of Global Strategic Marketing of Facial Aesthetics at Allergan. Earlier, she held strategic marketing positions at both Zimmer Biomet and Eli Lilly. Ms. Lask received an M.B.A from the University of Michigan and has a B.A. in marketing from Miami University, Oxford, Ohio. \nAbout CollPlant\nCollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collage...